ABCB4 and sclerosing cholangitis: We recently showed how genetic and pharmacological MGL inhibition could revert cholestatic liver disease, by using the Mdr2 (Abcb4) knockout model of sclerosing cholangitis/cholestasis [22] and total body knockout mice for Mgl challenged with cholestatic diet (3,5-diethoxycarbonyl-1,4-dihydrocollidine—DDC) [19].